News for PolyPid Ltd. (PYPD)

New Report Covers PolyPid's Latest Developments; After Blockbuster Phase 3 Results in Surgical Infection Prevention, Could This Israeli Innovator Become Big Pharma’s Most Coveted Acquisition Target?

On June 18, 2025, Roth Capital released its updated analyst rating for PolyPid (PYPD). Analyst Boobalan Pachaiyappan has chosen to maintain the current "Buy" ra

PolyPid (PYPD) received an update from analyst Roy Buchanan at JMP Securities on June 17, 2025. The analyst has maintained the "Market Outperform" rating for Po

Roth Capital has revised its price target for PolyPid (PYPD), setting it at $9, a reduction from the previous $12. This adjustment is driven by an anticipated i

Citizens JMP has revised its price target for PolyPid (PYPD) from $16 to $14 while maintaining an Outperform rating on the stock. This update follows PolyPid's

The Company Anticipates that with this Additional Funding, PolyPid's Runway would be Extended beyond Anticipated U.S. Food and Drug Administration (”œFDA”) A

PolyPid (PYPD) secures $26.7 million through warrant exercises following positive Phase 3 trial results. Funds to be used for NDA submission, launch pre

On June 9th, PolyPid Ltd.* announced landmark topline results from its pivotal SHIELD II Phase 3 trial, demonstrating that D-PLEX100 achieved statistically significant reductions across all primary and secondary

On June 9, 2025, HC Wainwright & Co. analyst Brandon Folkes announced an update on PolyPid (PYPD), maintaining a "Buy" rating for the biotechnology company.In a

H.C. Wainwright analyst Brandon Folkes has elevated the price target for PolyPid (PYPD) from $11 to $13, while maintaining a Buy rating. This decision comes aft

PolyPid (PYPD) has revealed promising topline results from its critical SHIELD II Phase 3 trial concerning D-PLEX100, a treatment designed to prevent surgical s

Shares of Circle Internet Group CRCL rose sharply in today's pre-market trading on continued IPO launch strength. Circle Internet Group, the issuer of the USDC...

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiat...

California-based Liminatus Pharma, Inc. (LIMN) is up over 83 percent in Thursday's pre-market trading. The following are some of the other stocks making big moves in Thursday's pre-market trading.

Release Date: May 14, 2025For the complete transcript of the earnings call, please refer to the full earnings call transcript. Positive Points PolyPid Ltd (PYPD

Refinitiv StreetEvents Event TranscriptE D I T E D V E R S I O NPYPD.OQ - PolyPid LtdQ1 2025 PolyPid Ltd Earnings CallMay 14, 2025 / 12:30PM GMT =============

PolyPid Ltd. (NASDAQ:PYPD) Q1 2025 Earnings Call May 14, 2025 8:30 AM ETCompany ParticipantsBrian Ritchie - Investor RelationsDikla Czaczkes Akselbrad -...

PYPD is set to organize a virtual meeting on May 19, facilitated by Craig-Hallum. This event aims to provide insights amid current market fluctuations. Particip

PolyPid (PYPD) is gearing up for significant milestones in 2025. The company remains optimistic about the SHIELD II Phase 3 trial, now considered less risky. Th